Alkermes Plc (NASDAQ:ALKS) SVP Laurie Keating sold 6,249 shares of Alkermes stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of Alkermes Plc (NASDAQ:ALKS) traded up $0.32 during midday trading on Thursday, reaching $52.12. The company’s stock had a trading volume of 640,200 shares, compared to its average volume of 852,385. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23. Alkermes Plc has a 1 year low of $46.42 and a 1 year high of $63.40.
Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, October 26th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.04. Alkermes had a negative return on equity of 7.27% and a negative net margin of 20.12%. The firm had revenue of $217.40 million for the quarter, compared to the consensus estimate of $231.29 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. equities research analysts anticipate that Alkermes Plc will post -0.59 EPS for the current fiscal year.
ALKS has been the topic of a number of research analyst reports. ValuEngine upgraded Alkermes from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Jefferies Group set a $69.00 price target on Alkermes and gave the company a “buy” rating in a report on Friday, August 25th. Citigroup set a $62.00 price target on Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. Credit Suisse Group lowered their price target on Alkermes from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. Finally, Barclays set a $50.00 price target on Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $63.55.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.